drugset / Trial / NCT00235014

A Study for Prevention of Kidney Disease in Diabetic Patients (BENEDICT)

NCT00235014 ↗

Phase 4 Completed 1204 enrolled Abbott
RandomizedParallel-groupDouble-blindTreatment

Summary

The BENEDICT study is conducted to examine the effects of an ACE inhibitor, calcium channel blockade, a combination of these, and placebo, in the prevention of micro- and macro-albuminuria in Type 2 diabetic patients.

Timeline

Start
1997-03
Primary completion
2006-01
Completion
—

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Verapamil Other / unclassified 180 mg —
Comparator Verapamil Other / unclassified 240 mg —
Comparator trandolapril Small molecule 2 mg —